Chen, S.-H.S.-H.ChenLI-YU LIUJaing, T.-H.T.-H.JaingTseng, C.-K.C.-K.TsengLin, K.-L.K.-L.LinLui, T.-N.T.-N.Lui2018-09-102018-09-102008http://www.scopus.com/inward/record.url?eid=2-s2.0-53749105471&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/338617The authors sought to evaluate the treatment outcome of children with medulloblastoma at a single institution. Forty-two children were analyzed. Eighty-six percent of the children who received chemotherapy were treated with cisplatin-based chemotherapy. No factors were found to affect outcome significantly. Compared with children treated before 1994 at the same institution, the median survival time was significantly longer (40 vs. 25 months, p =.0003). The authors conclude that some improvement of treatment outcome for children with medulloblastoma seemed to be achieved. Copyright ? Informa Healthcare USA, Inc.Children; Medulloblastoma; Outcome; Survival; Treatment[SDGs]SDG3cisplatin; etoposide; adolescent; article; cancer radiotherapy; cancer surgery; cancer survival; child; clinical article; clinical protocol; disease free survival; drug dose escalation; female; human; infant; male; medulloblastoma; multiple cycle treatment; multivariate analysis; outcome assessment; overall survival; retrospective study; survival time; therapy effect; treatment outcome; treatment response; Adolescent; Antineoplastic Agents, Phytogenic; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Etoposide; Female; Humans; Infant; Male; Medulloblastoma; Multivariate Analysis; Radiation-Sensitizing Agents; Survival Analysisjournal article10.1080/08880010802243979